December 04, 2025
December 03, 2025
New credential elevates GI nutrition collaboration
December 03, 2025
Ranitidine’s return 'unlikely to provide greater clinical benefit'
December 03, 2025
Mass Spec Roundup: Gold, G-Proteins, and Gray Seals…
December 02, 2025
Evaluating the benefit-risk profile of upadacitinib in IBD
December 02, 2025
‘Liver Cancer Has Disappeared in Children’: But for How Long?
Latest Headlines
View More
December 04, 2025
Your Guide to Weathering the PFAS Storm
December 03, 2025
New credential elevates GI nutrition collaboration
December 03, 2025
Ranitidine’s return 'unlikely to provide greater clinical benefit'
December 03, 2025
Mass Spec Roundup: Gold, G-Proteins, and Gray Seals…
December 02, 2025
Evaluating the benefit-risk profile of upadacitinib in IBD
December 02, 2025
‘Liver Cancer Has Disappeared in Children’: But for How Long?
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Trending Now
1
AGA unveils new clinical practice guideline for Crohn's disease
2
FDA Approves Reformulated Ranitidine
3
High Poultry Intake May Be Linked to GI Cancer Mortality
4
Thanksgiving Herbs: Health Benefits Explored
5
Mediterranean diet beats traditional dietary advice in IBS
6
GLP-1s and Tirzepatide: Similar GI Risk
Conference Coverage
2025 ASCO GI
2025 ASCO Annual Meeting
ESMO Congress 2025
Clinical Guidelines
View More
December 01, 2025
WHO Issues Conditional GLP-1 Obesity Guidelines
Commentary & Perspectives
View More
July 31, 2025
‘Victim-Blaming’ in Public Health?
November 22, 2024
FDA Official Expects Tightened Vaccine Review
February 14, 2020
Understanding the Human Microbiome and its Therapeutic Potential
FDA & Government News
View More
December 03, 2025
Ranitidine’s return 'unlikely to provide greater clinical benefit'
December 02, 2025
‘Liver Cancer Has Disappeared in Children’: But for How Long?
November 25, 2025
FDA Approves Reformulated Ranitidine
November 21, 2025
Which Antidepressants Shift Physiology?
Business Management
View More
